Spherix Inc (NASDAQ:SPEX)

CAPS Rating: 1 out of 5

The Company operates via two principal segments, BioSpherix and InfoSpherix. BioSpherix develops proprietary products for commercial applications. InfoSpherix provides contact center information and reservation services for government and industry.


Player Avatar zzlangerhans (99.85) Submitted: 9/24/2010 7:30:42 PM : Underperform Start Price: $14.80 SPEX Score: +23.55

I am deeply honored to be the only player to have ever rated Spherix on CAPS. I've been hoping that this stub would become ratable before topline results of the NEET phase III trial of Naturlose (tagatose) in type II diabetes. Until 2007, Naturlose was a side project of a company that generated most of their revenue from booking reservations in national parks. The company sold that business to focus exclusively on the phase III trial of Naturlose which was due to yield topline results mid-September. That's right, it's late September now. Not a good omen, but fortunate for me as I strongly believe the tiral will show Naturlose to be ineffective. My understanding of the effects of tagatose in diabetes is that they are very limited and unlikely to affect the need for insulin or oral hypoglycemic medications. Sadly, there are no options available for Spherix.

Report this Post 4 Replies
Member Avatar whoitis (68.25) Submitted: 9/30/2010 2:39:48 PM
Recs: 0

You are so WRONG!! Have you been following SPEX in the last two years? I have made a small fortune. The results are actually going to be positive from the NEET phase 3 trial, as were the results of both phase 1 and phase 2 and the interim results for phase 3. The drug has not received as much attention as either I nor the company believes it should with respect to its value in treating type 2 diabetes, but it was named one of the TOP 10 compounds in development for treatment of C/V Metabolic disorders. There is indeed a beneficial role for Naturlose/D-Tagatose somewhere in the health industry or pharma market. It has a broad spectrum of applications. The company, which has always been quite small, needs some assistance and financial backing with a partner that believes in the manner I do. Besides, it isn't a huge investment right now if I am wrong anyway, but the potential to gain is huge. WATCH AND SEE!!! The results of that clinical trial, while a bit late in coming out, are going to be positive overall.

Member Avatar zzlangerhans (99.85) Submitted: 10/2/2010 10:17:51 PM
Recs: 2

The opinion of the village idiot has been duly noted

Member Avatar whoitis (68.25) Submitted: 10/4/2010 8:41:26 AM
Recs: 0

Wow! Was that the best you could come up with? I'm thinking...why even bother? Still, worst-case scenario for me is I end up being wrong, better that than being an unnecessarily rude prick though, right? On the bright side, we don't even have to wait and see who the real idiot is in the end now, do we?

Member Avatar zzlangerhans (99.85) Submitted: 10/13/2010 2:34:09 PM
Recs: 2

Worst case scenario came true - you were wrong, and we found out who the real idiot was. Did your small fortune get a lot smaller?

Featured Broker Partners